Beam Therapeutics Inc. (BEAM) — Stock Score Summary

Beam Therapeutics Inc. (BEAM) has a MoatMap StockRank of 38/100 based on Quality (31/100), Value (37/100), and Momentum (56/100) factor scores. The current signal is HOLD. Pre-revenue gene editing biotech with high cash burn, unsuitable for a concentrated quality-first portfolio.

Beam Therapeutics Inc. is a leading biotechnology company pioneering the development of precision genetic medicines using its proprietary base editing technology. This novel gene-editing platform enables targeted, single-base changes to DNA without cutting the double helix, offering a potential path to cure a wide range of genetic diseases. Beam holds a significant competitive advantage through its foundational intellectual property and broad pipeline, aiming for transformative therapeutic impact.

Key Financial Metrics

Price$29.55
Market Cap$3.4B
P/E (Forward)-6.92
Price/Book2.80
Return on Equity-5.8%
Return on Invested Capital-27.7%
Debt/Equity21.54
Gross Margin-146.9%
Operating Margin-337.8%
Revenue Growth324.9%
Free Cash Flow$-234M

Beam Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Beam Therapeutics Inc.’s (BEAM) StockRank?
MoatMap’s StockRank for Beam Therapeutics Inc. (BEAM) is 38/100, with a Hold signal. It is a composite of Quality (31), Value (37), and Momentum (56) factor ranks across MoatMap’s 19,000+ stock universe.
Does Beam Therapeutics Inc. have an economic moat?
Beam Therapeutics Inc. (BEAM) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Beam Therapeutics Inc. a buy, hold, or sell?
MoatMap’s current signal for Beam Therapeutics Inc. (BEAM) is Hold, based on a StockRank of 38/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Beam Therapeutics Inc. in?
Beam Therapeutics Inc. (BEAM) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksBEAM deep dive reportAI ChampionsHow we score stocksSense-check another stock